Shanghai Fosun Pharmaceutical's (HKG:2196, SHA:600196) unit, Shanghai MicroH Therapeutics, will conduct a phase I clinical trial on LBP-ShC4 in the US after receiving approval from the US Food and Drug Administration, according to a Hong Kong Stock Exchange filing on May 9.
The drug is intended to be used for the treatment of androgenetic alopecia, the filing said.
The Chinese pharmaceutical company invested 17 million yuan in the research and development of the drug as of April.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。